中国生物制药全资收购礼新,创新加速发展

浦银国际证券
18 Jul

公司以极具吸引力的估值全资收购优秀的早期Biotech企业礼新医药给市场带来了正面惊喜。重申“买入”评级,上调目标价至7.85港元。公司宣布以5亿美元付款净额全资收购礼新医药,估值极具吸引力,显示出公司强大的BD能力及加速发展创新药的决心:公司近日宣布将以不超过9.5092亿美元的对价全资收购礼新医药以获得剩余95.09%股权(公司目前持有礼新医药4.91%股权),剔除礼新于交割日现金及银行存款...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10